The Lab Rats

The group is developing novel immunotherapies using the Adeno-associated virus (AAV) gene-therapy platform that are capable of not only preventing development of disease, but can also stop preexisting (reverse) disease in mouse models of Multiple Sclerosis.

PRINCIPAL INVESTIGATOR

Brad Hoffman

Dr. Hoffman is an Associate Professor and cellular immunologist with a major interest in immune modulation and tolerance induction using adeno-associated virus (AAV) gene therapy. Dr. Hoffman earned his Ph.D. in Immunology from Temple University School of Medicine in 2006. He subsequently performed postdoctoral research in gene therapy at University of Florida.

Brad Hoffman

UF Pediatric News

2020 Pediatric Progress Report

Welcome to the University of Florida Health 2020 Pediatric Progress Report, where we share news and updates from UF Health Shands Children’s Hospital. Read more about what makes our pediatric…

Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

Tryp Therapeutics (CSE: TRYP) (“Tryp”), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with…

The Florida Pediatrician, Winter 2021

The Florida Pediatrician is the peer-reviewed journal of the Florida Chapter of the American Academy of Pediatrics, published by the FCAAP Editorial Board for FCAAP members

Florida Providers See Increased Demand For Telehealth Visits

Dr. Michael Haller, professor and chief of pediatric endocrinology at UF, said his department switched almost completely to telemedicine for a while in March and April. Haller said his unit…